Targets › PIK3CG
8 programs from 8 companies in 34 trials: 16 Phase 1, 15 Phase 2, 3 Phase 3; Oncology, Infectious disease, Other; next expected readout Dec 2026.
Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. (UniProt, P48736)
Open in Phaseline: the race on PIK3CG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Celcuity | Gedatolisib Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 3 | Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast Cancer | Dec 2026 |
| SecuraBio | Duvelisib PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor | PIK3CD, PIK3CG | Phase 3 | Lymphoma; Newly Diagnosed Peripheral T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Recurrent Chronic Lymphocytic Leukemia … | Feb 2028 |
| Rhizen Pharmaceuticals | Tenalisib (RP6530) PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor | PIK3CD, PIK3CG | Phase 2 | Triple Negative Breast Cancer (TNBC) | Dec 2026 |
| National Cancer Institute (NCI) | Taselisib (GDC-0032) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 2 | Advanced Lymphoma | Mar 2027 |
| Restorbio | Dactolisib (BEZ235) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 2 | Respiratory Tract Infections; Covid19 | – |
| Eli Lilly | Samotolisib (LY3023414) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 1 | Breast Neoplasms; Endometrial Cancer | Dec 2026 |
| Sovargen | Paxalisib (SVG103) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 1 | Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation … | Feb 2027 |
| Stelexis BioSciences | Eganelisib PI3-kinase p110-gamma subunit inhibitor | PIK3CG | Phase 1 | AML, Adult; Leukemia, Myeloid | Dec 2027 |
Breast Cancer (2) Endometrial Cancer (2) Respiratory Tract Infections (1) Covid19 (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1) TNBC - Triple-Negative Breast Cancer (1) Advanced Lymphoma (1) Breast Neoplasms (1) Triple Negative Breast Cancer (TNBC) (1) Focal Cortical Dysplasia (1) Primary Central Nervous System Lymphoma (1) Glioblastoma (1)
small molecule (7), mixed (1)
Restorbio (1) Celcuity (1) National Cancer Institute (NCI) (1) Eli Lilly (1) Rhizen Pharmaceuticals (1) Sovargen (1) SecuraBio (1) Stelexis BioSciences (1)
PIK3R1 (5) PIK3CB (5) PIK3CA (5) MTOR (3) PIK3R2 (2) PIK3CD (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.